AstraZeneca (AZN) Announces Strategic Research Collaboration with CSPC Pharmaceuticals
A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.
Under the agreement, the two companies will discover and develop pre-clinical candidates for various targets related to the treatment of diseases across chronic indications. This includes a pre-clinical small molecule oral therapy for immunological diseases.
CSPC would conduct the research in Shijiazhuang City, utilizing its AI-driven, dual-engine efficient drug discovery platform. The collaboration is expected to expand AstraZeneca PLC's (NASDAQ:AZN) presence in China following the announcement of a $2.5 billion investment to develop a new global strategic R&D center in Beijing earlier in the year.
AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.
While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
3 Supercharged Stocks Flashing Strong Momentum Signals
Several stocks have shown strong momentum in recent sessions as broader markets charge to all-time highs. Here's a look at some standout momentum movers that are just starting to pick up steam. 3 Momentum Names To Watch Benzinga's rankings system assigns scores to stocks based on momentum, growth, value and quality. The momentum score is a valuable metric for short-term trading strategies that aim to capture continuation of price trends. Identifying significant changes in momentum can help traders get ahead of potential changes in general stock direction. Benzinga's rankings system flagged three stocks that experienced significant changes in bullish momentum over the past week. BioXcel Therapeutics Inc (NASDAQ:BTAI) saw the biggest week-over-week jump in momentum score, moving from a score of 3.34 on Aug. 4 to a current score of 86.85. Shares of BioXcel Therapeutics, a biopharmaceutical company using AI to develop transformative medicines in neuroscience, have doubled over the past week and are up approximately 238% over the past month. BioXcel Therapeutics is currently trading well above its 50-day moving average of $2.11 and 100-day moving average of $1.92, indicating strong upward momentum. Key resistance is observed near the recent high of $7.36, while support can be identified around $6.67. Telos Corp (NASDAQ:TLS) also saw a strong surge in the momentum rankings this week, with a current score of 84.27, up from last week's score of 16.25. Multiple analysts lifted price targets ranging from $4 to $6 this week with shares up about 125% over the past five trading sessions. Telos is a provider of cyber, cloud and enterprise security solutions. The stock is currently trading well above its 50-day ($2.85), 100-day ($2.69) and 200-day ($3.02) moving averages, indicating a bullish trend and potential support levels at these averages. Jumia Technologies (NYSE:JMIA) saw its momentum score climb from 21.01 on Aug. 4 to 87.91 this week with shares up about 63% over the past week, according to Benzinga Pro. Jumia operates a pan-African e-commerce platform. The company is often referred to as the 'Amazon of Africa.' The stock is above its 50-day moving average of $4.22, indicating a bullish trend, while the 100-day and 200-day moving averages at $3.39 and $3.58, respectively, suggest strong support levels. Resistance is noted near the recent high of $7.85, which could act as a barrier for further upward movement. Price Actions: At the time of publication, BioXcel shares were down 12.65% at $5.94, while Telos shares were up 6.01% at $5.56 and Jumia shares were up 5.93% at $7.68, according to Benzinga Pro. Read Next: Bessent Wants Aggressive Fed Rate Cuts: 'We Should Be 150-175 Points Lower' Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Photo: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article 3 Supercharged Stocks Flashing Strong Momentum Signals originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Light & Wonder Faces Target Cuts as Analysts Eye EBITDA Risks, Despite Buy Ratings
Light & Wonder Inc. (NASDAQ: LNW) is one of the best cheap growth stocks to buy according to analysts. On August 8, 2025, Benchmark analyst Mike Hickey maintained a Buy rating on the stock but trimmed his price target from $100 to $90. One day earlier, on August 7, JPMorgan downgraded Light & Wonder from Overweight to Neutral and lowered its price target from $108 to $95. JPMorgan analysts expressed concern about the company's ability to meet its full-year 2025 EBITDA target through organic growth alone. The updated guidance includes EBITDA contributions from a recent acquisition. To hit the midpoint of that target, Light & Wonder would need to grow EBITDA by about 15% in the second half of 2025, a noticeable acceleration from its reported growth of 11% in Q1 and 7% in Q2. The firm also flagged uncertainty around free cash flow and leverage. Macquarie also updated its position on August 7, maintaining its Outperform rating but cutting its price target from $122 to $117. Light & Wonder Inc. (NASDAQ: LNW), headquartered in Las Vegas, Nevada, is a global developer and supplier of content and technology for the gaming and lottery industries. The company operates across three business segments: gaming, iGaming, and SciPlay, and provides hardware, systems, and digital platforms to casinos and online operators worldwide. While we acknowledge the potential of LNW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Court Lets Trump Block Billions of Dollars in Foreign Aid
(Bloomberg) -- The Trump administration can cut billions of dollars in foreign assistance funds approved by Congress for this year, a US appeals court ruled. Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' New York Warns of $34 Billion Budget Hole, Biggest Since 2009 Crisis Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets In a 2-1 decision on Wednesday, the appellate panel reversed a Washington federal judge who found that US officials were violating the Constitution's separation of powers principles by failing to authorize the money to be paid in line with what the legislative branch directed. The ruling is a significant win for President Donald Trump's efforts to dissolve the US Agency for International Development and broadly withhold funding from programs that have fallen out of favor with his administration, regardless of how Congress exercised its authority over spending. Trump's critics have assailed what they've described as a far-reaching power grab by the executive branch. The nonprofits and business that sued could ask all of the active judges on the US Court of Appeals for the DC Circuit to reconsider the three-member panel's decision. If the panel's decision stands, it wasn't immediately clear how much it would affect other lawsuits contesting a range of Trump administration funding freezes and cuts besides foreign aid. Judge Karen LeCraft Henderson wrote in the majority opinion that the challengers lacked valid legal grounds to sue over the Trump administration's decision to withhold the funds, also known as impoundment. The US Comptroller General — who leads an accountability arm of Congress — could sue under a specific law related to impoundment decisions, Henderson wrote, but the challengers couldn't bring a 'freestanding' constitutional claim or claim violations of a different law related to agency actions. Henderson, appointed by former President George H.W. Bush, was joined by Judge Greg Katsas, a Trump appointee. The court didn't reach the core question of whether the administration's unilateral decision to refuse to spend money appropriated by Congress is constitutional. Judge Florence Pan, nominated by former President Joe Biden, dissented, writing that her colleagues had turned 'a blind eye to the 'serious implications' of this case for the rule of law and the very structure of our government.' White House spokesperson Anna Kelly said in a statement that the appeals court 'has affirmed what we already knew – President Trump has the executive authority to execute his own foreign policy, which includes ensuring that all foreign assistance aligns with the America First agenda.' A lead attorney for the grant recipients did not immediately respond to a request for comment. The two consolidated cases before the appeals court only deal with money that Congress approved for the 2024 fiscal year, which ends on Sept. 30. Grantees are poised to lose access to funds if they haven't yet been approved to be spent by federal officials — a precursor to actual payouts — or unless a court order is in place. The administration lost one of its few battles before the US Supreme Court earlier this year in the foreign aid fight. In March, a majority of justices refused to immediately stop US District Judge Amir Ali's injunction taking effect while the legal fight went forward. Since then, however, the challengers have filed complaints with Ali that the administration is failing to obligate or pay out the funds. They've rebuffed the government's position that the delay is part of a legitimate effort to 'evaluate the appropriate next steps' and accused officials of angling to use a novel tactic to go around Congress in order to cut appropriated money. The Trump administration has dramatically scaled back the US government's humanitarian work overseas, slashing spending and personnel and merging the USAID into the State Department. The challengers say the foreign aid freeze has created a global crisis, and that the money is critical for malaria prevention, to address child malnutrition and provide postnatal care for newborns. The groups argued that the president and agency leaders couldn't defy Congress' spending mandates and didn't have discretion to decide that only some, let alone none, of the money appropriated by lawmakers should be paid. The president can ask Congress to withdraw appropriations but can't do it on his own, the challengers argued. The Justice Department argued Ali's order was an 'improper judicial intrusion into matters left to the political branches' and that the judge wrongly interfered in the 'particularly sensitive area of foreign relations.' The government also said that the Impoundment Control Act, which restricts the president from overruling Congress' spending decisions, wasn't a law that the nonprofits and business could sue to enforce. The challengers countered that Ali's order blocking the funding freeze was rooted in their constitutional separation-of-powers claim, not the impoundment law. The cases are Global Health Council v. Trump, 25-5097, and AIDS Vaccine Advocacy Coalition v. US Department of State, 25-5098, US Court of Appeals, DC Circuit. (Updated with White House comment.) Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Dubai's Housing Boom Is Stoking Fears of Another Crash The Social Media Trend Machine Is Spitting Out Weirder and Weirder Results Americans Are Getting Priced Out of Homeownership at Record Rates ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
